New insider activity at Henry Schein ( (HSIC) ) has taken place on March 11, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Kurt Kuehn of Henry Schein has sold 2,844 shares of the company’s stock in a transaction valued at $224,562, signaling a notable insider move at the healthcare products distributor.
Recent Updates on HSIC stock
Henry Schein shares reacted to a strong Q4 report, with revenue and earnings topping expectations on the back of the best sales growth in 15 quarters, led by dental equipment, specialty products, and technology, plus robust cash generation and buybacks. Analysts raising targets cited this improved operating momentum and Baird’s data showing a multi‑month rebound in dental patient demand, while still factoring in margin pressure, restructuring costs, and a 2026 “transition year” with earnings skewed to the back half.
Spark’s Take on HSIC Stock
According to Spark, TipRanks’ AI Analyst, HSIC is a Neutral.
The score is anchored by stable (but leveraged) fundamentals with strong 2025 free-cash-flow improvement, plus supportive technical momentum. These positives are moderated by a relatively full P/E and earnings-call risks around margin mix, restructuring uncertainty, and external pressures (tariffs/medical demand), despite constructive 2026 growth guidance and value-creation targets.
To see Spark’s full report on HSIC stock, click here.
More about Henry Schein
YTD Price Performance: 0.94%
Average Trading Volume: 1,363,279
Technical Sentiment Signal: Buy
Current Market Cap: $8.75B